Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. The Illumina Analysts: Baird ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback